Kymera Therapeutics (NASDAQ:KYMR) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Kymera from "sell" to "hold" and the stock carries a consensus "Moderate Buy" from analysts with an average target of $118.70.
• Kymera beat quarterly expectations, reporting EPS of ($0.71) versus ($0.89) expected and revenue of $34.37M (vs. $8.27M), a 55.5% year-over-year revenue increase.
• Insider selling has been significant, with insiders selling 380,734 shares (~$32.2M) over the past 90 days; the stock trades around $80.71 with a $6.59B market cap and a one-year range of $28.06–$103.00.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued to investors on Saturday.

Other equities research analysts also recently issued research reports about the stock. Barclays boosted their target price on shares of Kymera Therapeutics to $133.00 and gave the company an "overweight" rating in a research note on Tuesday, January 27th. Citigroup lifted their price target on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a "buy" rating in a report on Monday, March 2nd. Morgan Stanley restated an "overweight" rating and issued a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday. UBS Group upped their price objective on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a "buy" rating in a research note on Tuesday, March 3rd. Finally, BTIG Research dropped their price objective on shares of Kymera Therapeutics from $138.00 to $134.00 and set a "buy" rating for the company in a report on Thursday, February 26th. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Kymera Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $118.70.

Kymera Therapeutics Trading Down 0.4%

Shares of KYMR opened at $80.71 on Friday. The stock has a market cap of $6.59 billion, a PE ratio of -21.93 and a beta of 2.06. Kymera Therapeutics has a 1 year low of $28.06 and a 1 year high of $103.00. The stock has a 50 day simple moving average of $84.52 and a 200-day simple moving average of $76.23.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 26.69% and a negative net margin of 611.94%.The firm had revenue of $34.37 million for the quarter, compared to analysts' expectations of $8.27 million. During the same period in the prior year, the business posted ($0.82) earnings per share. The business's revenue was up 55.5% compared to the same quarter last year. On average, sell-side analysts forecast that Kymera Therapeutics will post -3.65 EPS for the current fiscal year.

Insider Activity

In other news, insider Noah Goodman sold 8,264 shares of the business's stock in a transaction on Thursday, April 9th. The stock was sold at an average price of $87.50, for a total transaction of $723,100.00. Following the completion of the sale, the insider owned 53,542 shares in the company, valued at $4,684,925. The trade was a 13.37% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Nello Mainolfi sold 30,000 shares of the company's stock in a transaction on Wednesday, February 25th. The shares were sold at an average price of $90.26, for a total value of $2,707,800.00. Following the transaction, the chief executive officer directly owned 666,195 shares in the company, valued at $60,130,760.70. This trade represents a 4.31% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 380,734 shares of company stock worth $32,193,902. 16.01% of the stock is owned by company insiders.

Institutional Trading of Kymera Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. SG Americas Securities LLC lifted its holdings in Kymera Therapeutics by 169.1% in the fourth quarter. SG Americas Securities LLC now owns 22,693 shares of the company's stock valued at $1,766,000 after buying an additional 14,261 shares during the period. Hudson Bay Capital Management LP grew its holdings in Kymera Therapeutics by 362.7% during the 3rd quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company's stock worth $1,309,000 after acquiring an additional 18,134 shares during the period. Federated Hermes Inc. bought a new stake in shares of Kymera Therapeutics during the 3rd quarter valued at $31,622,000. Candriam S.C.A. lifted its stake in shares of Kymera Therapeutics by 24.4% in the 3rd quarter. Candriam S.C.A. now owns 191,639 shares of the company's stock valued at $10,847,000 after purchasing an additional 37,536 shares during the period. Finally, Knights of Columbus Asset Advisors LLC acquired a new position in shares of Kymera Therapeutics in the 3rd quarter valued at $1,069,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body's natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company's proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company's pipeline emphasizes immunology and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.